NOVEL PRE-TREATMENT PROCESS FOR LIBERATION OF METALS FROM WASTE PRINTED CIRCUIT BOARDS USING ORGANIC SOLUTION
    72.
    发明申请
    NOVEL PRE-TREATMENT PROCESS FOR LIBERATION OF METALS FROM WASTE PRINTED CIRCUIT BOARDS USING ORGANIC SOLUTION 有权
    使用有机溶液从废弃印刷电路板中分离金属的新型预处理工艺

    公开(公告)号:US20100071507A1

    公开(公告)日:2010-03-25

    申请号:US12310324

    申请日:2008-07-28

    IPC分类号: C22B1/00

    摘要: The present invention relates to a method for recovering valuable metals contained in printed circuit boards of waste electronic machine, and more particularly, to a method for recovering valuable metals from waste printed circuit boards by separating several plastic layers laminated using an organic solution and then separating plastic components from metal components using an electrostatic separation process.According to the present invention, it is possible to separate the non-metal containing the plastic components and the metal components from the waste printed circuit boards by separating the several plastic layers laminated via simple pre-process using an organic solvent and obtain the metal recovery ratio of 99.99% via the pre-process and an electrostatic separation process.

    摘要翻译: 本发明涉及一种用于回收废电子机的印刷电路板中所含的有价金属的方法,更具体地说,涉及一种通过分离使用有机溶液层压的多个塑料层然后分离的废旧印刷电路板中的有价金属来回收的方法 使用静电分离工艺的金属部件的塑料部件。 根据本发明,可以通过使用有机溶剂通过简单的预处理分离多个层压的塑料层,从而将废塑料组分和金属组分的非金属与废印刷电路板分离,并获得金属回收 通过预处理和静电分离过程的比例为99.99%。

    Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising an Antibody Against Tgf-Beta
    73.
    发明申请
    Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising an Antibody Against Tgf-Beta 审中-公开
    用于治疗包含抗Tgf-β的抗体的Avellino角膜营养不良的药物组合物

    公开(公告)号:US20080267946A1

    公开(公告)日:2008-10-30

    申请号:US11817023

    申请日:2006-03-08

    IPC分类号: A61K39/395 A61P27/02

    CPC分类号: C07K16/22 A61K2039/505

    摘要: The present invention relates to a medicine for treating Avellino corneal dystrophy (ACD), and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy containing an antibody against TGF-β as an effective ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms of a patient with severe Avellino corneal dystrophy due to TGF-β induced by exposure to intense light, such as UV etc.

    摘要翻译: 本发明涉及用于治疗阿维拉氏角膜营养不良症(ACD)的药物,更具体地,涉及含有抗TGF-β抗体作为有效成分的Avellino角膜营养不良药用组合物。 本发明的药物组合物具有通过暴露于强光如UV等引起的由TGF-β引起的严重的Avellino角膜营养不良症状改善的效果。

    Mobile phone with USB interface
    74.
    发明授权
    Mobile phone with USB interface 失效
    手机带USB接口

    公开(公告)号:US07412259B2

    公开(公告)日:2008-08-12

    申请号:US11062984

    申请日:2005-02-22

    IPC分类号: H04B1/00 H04M1/00

    摘要: A mobile phone having a USB interface and including a main body and a battery pack removably mounted to the main body is provided. The mobile phone includes a USB connector that may be connected to an external device to allow data transmission between the external device and the mobile phone; a holding unit for containing the USB connector and from which the USB connector may be withdrawn; and a housing mounted in the mobile phone and including a flash memory for storing data, and a controller for controlling a data signal of the flash memory through the USB connector.

    摘要翻译: 提供一种具有USB接口并且包括可拆卸地安装到主体的主体和电池组的移动电话。 手机包括可连接到外部设备的USB连接器,以允许外部设备和移动电话之间的数据传输; 用于容纳所述USB连接器的保持单元,并且所述USB连接器可从所述保持单元中取出; 以及安装在移动电话中并且包括用于存储数据的闪存的外壳,以及用于通过USB连接器控制闪存的数据信号的控制器。

    Agent for reduction of scar formation by using wound alkalinization
    77.
    发明申请
    Agent for reduction of scar formation by using wound alkalinization 审中-公开
    通过使用伤口碱化来减少瘢痕形成的药剂

    公开(公告)号:US20050136126A1

    公开(公告)日:2005-06-23

    申请号:US11028767

    申请日:2005-01-03

    IPC分类号: A61K33/00 A61K33/42

    摘要: The present invention relates to an agent for reducing scar formation, which inhibits the scar formation by injecting sodium bicarbonate to the dermis tissue of the wound with a syringe to directly control pH of the wound site, namely, by alkalinizing the wound to inactivate TGF-β. According to the present invention, the agent for reducing scar formation by controlling the wound healing process can be clinically and immediately applied to the treatment of tylosis scar and keloid, etc., and is effective to the treatment of intractable fibrosis diseases. Also, the invention can be widely applied in many ways as an easy tool which can control the action of TGF-β in a living organism.

    摘要翻译: 本发明涉及一种用于减少瘢痕形成的药剂,其通过用注射器将碳酸氢钠注入伤口的真皮组织来抑制瘢痕形成,以直接控制伤口部位的pH,即通过使伤口碱化以使TGF- 测试版 根据本发明,通过控制伤口愈合过程来减少瘢痕形成的药剂可以临床上立即应用于治疗泰乐菌瘢痕和瘢痕疙瘩等,对于治疗难治性纤维化疾病是有效的。 此外,本发明可以以许多方式广泛应用,作为可以控制活体中TGF-β的作用的简单工具。